JP2018529320A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018529320A5 JP2018529320A5 JP2018505723A JP2018505723A JP2018529320A5 JP 2018529320 A5 JP2018529320 A5 JP 2018529320A5 JP 2018505723 A JP2018505723 A JP 2018505723A JP 2018505723 A JP2018505723 A JP 2018505723A JP 2018529320 A5 JP2018529320 A5 JP 2018529320A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- seq
- cell
- cancer
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562201289P | 2015-08-05 | 2015-08-05 | |
| US62/201,289 | 2015-08-05 | ||
| GBGB1513921.5A GB201513921D0 (en) | 2015-08-05 | 2015-08-06 | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| GB1513921.5 | 2015-08-06 | ||
| PCT/EP2016/068727 WO2017021527A2 (en) | 2015-08-05 | 2016-08-05 | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020191407A Division JP7142957B2 (ja) | 2015-08-05 | 2020-11-18 | 前立腺がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018529320A JP2018529320A (ja) | 2018-10-11 |
| JP2018529320A5 true JP2018529320A5 (2) | 2019-09-12 |
| JP6884752B2 JP6884752B2 (ja) | 2021-06-09 |
Family
ID=54200350
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018505723A Expired - Fee Related JP6884752B2 (ja) | 2015-08-05 | 2016-08-05 | 前立腺がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2020191407A Active JP7142957B2 (ja) | 2015-08-05 | 2020-11-18 | 前立腺がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2022142129A Pending JP2022191218A (ja) | 2015-08-05 | 2022-09-07 | 前立腺がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2024215091A Pending JP2025038025A (ja) | 2015-08-05 | 2024-12-10 | 前立腺がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020191407A Active JP7142957B2 (ja) | 2015-08-05 | 2020-11-18 | 前立腺がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2022142129A Pending JP2022191218A (ja) | 2015-08-05 | 2022-09-07 | 前立腺がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2024215091A Pending JP2025038025A (ja) | 2015-08-05 | 2024-12-10 | 前立腺がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
Country Status (36)
| Country | Link |
|---|---|
| US (24) | US9908920B2 (2) |
| EP (4) | EP3854801A3 (2) |
| JP (4) | JP6884752B2 (2) |
| KR (1) | KR102943979B1 (2) |
| CN (2) | CN114395013A (2) |
| AR (1) | AR105817A1 (2) |
| AU (8) | AU2016303021B2 (2) |
| BR (1) | BR112018001687A2 (2) |
| CA (3) | CA3110640A1 (2) |
| CL (7) | CL2018000324A1 (2) |
| CO (1) | CO2018002202A2 (2) |
| CR (6) | CR20200434A (2) |
| CY (1) | CY1123854T1 (2) |
| DK (1) | DK3331900T3 (2) |
| EA (1) | EA201890440A1 (2) |
| ES (1) | ES2862400T3 (2) |
| GB (1) | GB201513921D0 (2) |
| HR (1) | HRP20210709T8 (2) |
| HU (1) | HUE053657T2 (2) |
| IL (2) | IL310078A (2) |
| LT (1) | LT3331900T (2) |
| MA (4) | MA46022B1 (2) |
| MD (1) | MD3331900T2 (2) |
| MX (2) | MX2018001421A (2) |
| MY (3) | MY202812A (2) |
| PE (2) | PE20180695A1 (2) |
| PH (1) | PH12018500189A1 (2) |
| PL (1) | PL3331900T3 (2) |
| PT (1) | PT3331900T (2) |
| RS (1) | RS61713B1 (2) |
| SG (1) | SG10202001660YA (2) |
| SI (1) | SI3331900T1 (2) |
| TW (3) | TWI829618B (2) |
| UA (1) | UA125816C2 (2) |
| WO (1) | WO2017021527A2 (2) |
| ZA (1) | ZA201800513B (2) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2508923A (en) * | 2012-12-17 | 2014-06-18 | Bombardier Transp Gmbh | Inductive power transfer system having inductive sensing array |
| PL3456339T3 (pl) | 2013-08-05 | 2022-03-21 | Immatics Biotechnologies Gmbh | Nowa immunoterapia przeciwko szeregu nowotworom, takim jak rak płuc, w tym nsclc |
| WO2021173560A1 (en) | 2020-02-24 | 2021-09-02 | Immatics US, Inc. | Methods for expanding t cells for the treatment of cancer and related malignancies |
| GB201513921D0 (en) * | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| SI3331891T1 (sl) | 2015-08-05 | 2022-04-29 | Eisai R&D Management Co., Ltd. | Postopek priprave v bistvu diastereomerno čistega fosforodiamidatnega oligomera, fosforodiamidatni oligomer izdelan po takem postopku in farmacevtski sestavek, ki vsebuje tak fosforodiamidatni oligomer |
| PH12022551111A1 (en) | 2015-10-05 | 2023-08-23 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
| RU2729116C2 (ru) | 2015-12-16 | 2020-08-04 | Гритстоун Онколоджи, Инк. | Идентификация, производство и применение неоантигенов |
| JP7075125B2 (ja) | 2016-05-25 | 2022-05-25 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ |
| GB201609193D0 (en) | 2016-05-25 | 2016-07-06 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
| EP4317432A3 (en) | 2016-12-08 | 2024-04-17 | Immatics Biotechnologies GmbH | T cell receptors with improved pairing |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| US11807662B2 (en) | 2017-05-16 | 2023-11-07 | The Johns Hopkins University | MANAbodies and methods of using |
| SG11202000025SA (en) | 2017-07-14 | 2020-02-27 | Immatics Biotechnologies Gmbh | Improved dual specificity polypeptide molecule |
| DE102017115966A1 (de) | 2017-07-14 | 2019-01-17 | Immatics Biotechnologies Gmbh | Polypeptidmolekül mit verbesserter zweifacher Spezifität |
| KR20260039788A (ko) | 2017-10-10 | 2026-03-20 | 시애틀 프로젝트 코포레이션 | 핫스팟을 이용한 신생항원 동정 |
| CA3083097A1 (en) | 2017-11-22 | 2019-05-31 | Gritstone Oncology, Inc. | Reducing junction epitope presentation for neoantigens |
| DE102017127984B4 (de) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen |
| EP3749753B1 (en) | 2018-02-09 | 2025-04-02 | Immatics US, Inc. | Methods for manufacturing t cells |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| CA3136405A1 (en) * | 2018-06-01 | 2019-12-05 | Geneoscopy, Inc. | Detection method for cancer using rna biomarkers |
| US10925947B2 (en) | 2018-06-29 | 2021-02-23 | Immatics Biotechnologies Gmbh | A*03 restricted peptides for use in immunotherapy against cancers and related methods |
| TW202019955A (zh) | 2018-07-31 | 2020-06-01 | 德商英麥提克生物技術股份有限公司 | B*07 限制肽和肽組合的抗癌免疫治療和相關方法 |
| US11945850B2 (en) | 2018-09-17 | 2024-04-02 | Immatics Biotechnologies Gmbh | B*44 restricted peptides for use in immunotherapy against cancers and related methods |
| TW202024121A (zh) | 2018-09-18 | 2020-07-01 | 德商英麥提克生物技術股份有限公司 | A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法 |
| US12583895B2 (en) | 2019-02-12 | 2026-03-24 | Vanderbilt University | Polypeptides for restoring endothelial function and methods of use thereof |
| WO2020191172A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| WO2020243134A1 (en) | 2019-05-27 | 2020-12-03 | Immatics US, Inc. | Viral vectors and their use in adoptive cellular therapy |
| MX2021015033A (es) | 2019-06-06 | 2022-01-18 | Immatics Biotechnologies Gmbh | Clasificacion con contraseleccion utilizando peptidos de secuencias similares. |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| AU2021256477A1 (en) * | 2020-04-14 | 2022-11-10 | Université de Montréal | Novel tumor-specific antigens for acute myeloid leukemia (AML) and uses thereof |
| TW202227616A (zh) | 2020-08-21 | 2022-07-16 | 美商英麥提克斯股份有限公司 | 分離ｃｄ８＋選擇ｔ細胞的方法 |
| WO2022125507A1 (en) * | 2020-12-07 | 2022-06-16 | Iogenetics, Llc | Personalized immunotherapies |
| KR20230135589A (ko) | 2020-12-31 | 2023-09-25 | 이매틱스 유에스 인코포레이티드 | Cd8 폴리펩타이드, 조성물 및 이의 사용 방법 |
| US12162940B2 (en) | 2021-05-05 | 2024-12-10 | Immatics Biotechnologies Gmbh | BMA031 antigen binding polypeptides |
| EP4113120A1 (en) | 2021-06-28 | 2023-01-04 | Immatics Biotechnologies GmbH | Method of characterizing the binding characteristics between a peptide of interest and mhc molecules |
| US20230024554A1 (en) | 2021-06-28 | 2023-01-26 | Immatics Biotechnologies Gmbh | Method of characterizing the binding characteristics between a peptide of interest and mhc molecules |
| CN113527435B (zh) * | 2021-07-14 | 2022-06-07 | 呈诺再生医学科技(珠海横琴新区)有限公司 | 对前列腺癌细胞特异性识别的新型多肽及其衍生物与应用 |
| JP2024534825A (ja) | 2021-08-24 | 2024-09-26 | イマティクス ユーエス，アイエヌシー． | 条件付きリガンド交換により産生されたペプチドｍｈｃ複合体を使用する免疫細胞の選択 |
| TW202332765A (zh) | 2021-09-20 | 2023-08-16 | 美商英麥提克斯股份有限公司 | 用於ｔ細胞療法之ｔ細胞群體的單核球耗盡 |
| CN118541392A (zh) | 2021-09-28 | 2024-08-23 | 准星生物医药有限公司 | 多种形式的分子复合物 |
| EP4448108A1 (en) | 2021-11-08 | 2024-10-23 | Immatics Biotechnologies GmbH | Adoptive cell therapy combination treatment and compositions thereof |
| JP2025515604A (ja) | 2022-04-28 | 2025-05-20 | イマティクス ユーエス，アイエヌシー． | ドミナントネガティブＴＧＦβ受容体ポリペプチド、ＣＤ８ポリペプチド、細胞、組成物、およびその使用方法 |
| JP2025516189A (ja) | 2022-04-28 | 2025-05-27 | イマティクス ユーエス，アイエヌシー． | 膜結合型ｉｌ－１５、ｃｄ８ポリペプチド、細胞、組成物、およびそれらの使用方法 |
| JP2025515603A (ja) | 2022-04-28 | 2025-05-20 | イマティクス ユーエス，アイエヌシー． | Ｉｌ－１２ポリペプチド、ｉｌ－１５ポリペプチド、ｉｌ－１８ポリペプチド、ｃｄ８ポリペプチド、それらの組成物、およびそれらの使用方法 |
| US20230355678A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
| WO2025096649A1 (en) | 2023-11-01 | 2025-05-08 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| WO2025137979A1 (zh) * | 2023-12-28 | 2025-07-03 | 祺安（广州）生物科技有限公司 | 特异性多肽在制备治疗、预防前列腺癌的药物中的应用 |
| WO2026030428A2 (en) * | 2024-08-01 | 2026-02-05 | Regeneron Pharmaceuticals, Inc. | Prostate-specific antigen peptides and uses thereof |
Family Cites Families (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1037656A (en) | 1911-11-28 | 1912-09-03 | Thomas F Loughran | Prorating-weir. |
| US1178658A (en) | 1914-06-11 | 1916-04-11 | United Shoe Machinery Ab | Gripper mechanism for pulling-over machines. |
| US1165315A (en) | 1914-10-31 | 1915-12-21 | William F Cameron | Governor-valve. |
| US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| IL59007A (en) | 1978-12-22 | 1983-11-30 | Biogen Nv | Recombinant dna molecules coding for polypeptides displaying hepatitis b virus antigenicity,method of their production and compositions containing the same |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
| US4897445A (en) | 1986-06-27 | 1990-01-30 | The Administrators Of The Tulane Educational Fund | Method for synthesizing a peptide containing a non-peptide bond |
| US6037135A (en) | 1992-08-07 | 2000-03-14 | Epimmune Inc. | Methods for making HLA binding peptides and their uses |
| US9340577B2 (en) * | 1992-08-07 | 2016-05-17 | Epimmune Inc. | HLA binding motifs and peptides and their uses |
| CN1118572A (zh) | 1993-03-05 | 1996-03-13 | 萨依特尔有限公司 | Hla-a2.1组合肽及其用途 |
| AU6852594A (en) | 1993-06-03 | 1995-01-03 | Therapeutic Antibodies Inc. | Production of antibody fragments |
| US20040157780A1 (en) * | 1993-11-29 | 2004-08-12 | Epimmune Inc. | CTL inducing peptides from c-erb2 (HER-2/neu) |
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| US6824993B2 (en) * | 1995-06-06 | 2004-11-30 | Human Genome Sciences, Inc. | Antibodies that bind human prostate specific G-protein receptor HPRAJ70 |
| ES2203782T3 (es) | 1996-01-17 | 2004-04-16 | Imperial College Innovations Limited | Inmunoterapia que utiliza linfocitos t citotoxicos (ctl). |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| DE19623825C1 (de) | 1996-06-14 | 1998-01-08 | Rottefella As | Langlauf- oder Tourenskibindung |
| AU4086397A (en) * | 1996-09-06 | 1998-03-26 | Centocor Inc. | Monoclonal antibodies specific for prostate specific antigen and methods of detecting prostate specific antigen |
| US7008772B1 (en) * | 1997-02-25 | 2006-03-07 | Corixa Corporation | Compounds for immunodiagnosis of prostate cancer and methods for their use |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US20070020327A1 (en) * | 1998-11-10 | 2007-01-25 | John Fikes | Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions |
| AU7994200A (en) | 1999-10-04 | 2001-05-10 | Corixa Corporation | Compositions and methods for therapy and diagnosis of prostate cancer |
| US7361338B2 (en) * | 1999-10-05 | 2008-04-22 | Agensys, Inc. | Methods to inhibit growth of prostate cancer cells |
| AU7753700A (en) * | 1999-10-07 | 2001-05-10 | Schering Aktiengesellschaft | Dna encoding prost 07 polypeptide |
| EP1230364A2 (en) * | 1999-11-12 | 2002-08-14 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| IL150732A0 (en) * | 2000-01-14 | 2003-02-12 | Corixa Corp | Prostate specific polypeptides, polynucleotides that encode said polypeptides and pharmaceutical compositions containing the same |
| WO2001057252A2 (en) | 2000-02-04 | 2001-08-09 | Aeomica, Inc. | Methods and apparatus for high-throughput detection and characterization of alternatively spliced genes |
| US20030219806A1 (en) * | 2000-02-22 | 2003-11-27 | Millennium Pharmaceuticals, Inc. | Novel 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 and 33751 molecules and uses therefor |
| US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
| CA2403909A1 (en) * | 2000-03-27 | 2001-10-04 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| DE60142475D1 (de) | 2000-03-27 | 2010-08-12 | Technion Res And Dev Of Founda | Einkettige haupthistokompatibilitätskomplexe der klasse i (mhc-i), kodierende konstrukte und methoden ihrer erzeugung |
| EP1274844A2 (en) * | 2000-03-31 | 2003-01-15 | Curagen Corporation | G-protein coupled receptors and nucleic acids encoding same |
| US7834146B2 (en) * | 2000-05-08 | 2010-11-16 | Monsanto Technology Llc | Recombinant polypeptides associated with plants |
| EP2322228B1 (en) | 2000-06-05 | 2018-01-10 | Altor BioScience Corporation | T cell receptor fusion proteins and conjugates and methods of use thereof |
| GB0015722D0 (en) * | 2000-06-27 | 2000-08-16 | Smithkline Beecham Sa | Vaccine |
| WO2002014485A2 (en) * | 2000-08-11 | 2002-02-21 | Mount Sinai Hospital | Kallikrein gene |
| EP1911461B1 (en) * | 2000-10-19 | 2011-12-07 | Epimmune Inc. | HLA class I and II binding peptides and their uses |
| US7048931B1 (en) * | 2000-11-09 | 2006-05-23 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US7919467B2 (en) | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| AU2002246708A1 (en) * | 2000-12-15 | 2002-08-12 | Agensys, Inc. | Nucleic acid and encoded zinc transporter protein entitled 108p5h8 useful in treatment and detection of cancer |
| US20030109692A1 (en) * | 2000-12-18 | 2003-06-12 | Muralidhara Padigaru | Novel proteins and nucleic acids encoding same |
| AUPR402201A0 (en) * | 2001-03-27 | 2001-04-26 | Queensland University Of Technology | Polynucleotides and polypeptides linked to cancer and/or benign tumours |
| CA2458915A1 (en) | 2001-08-31 | 2003-03-13 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 205p1b5 useful in treatment and detection of cancer |
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| AU2003216341A1 (en) | 2002-02-20 | 2003-09-09 | Dyax Corporation | Mhc-peptide complex binding ligands |
| DE10215321A1 (de) * | 2002-04-02 | 2003-10-23 | Metagen Pharmaceuticals Gmbh | Trp-p8 Splice Varianten und regulatorische RNA |
| EP2301972A1 (en) * | 2002-08-12 | 2011-03-30 | The Council Of The Queensland Institute Of Medical Research | Method to prepare immunogenic lipopeptides comprising T-helper and B-cell epitopes |
| AU2003256912A1 (en) * | 2002-08-16 | 2004-03-03 | Yeda Research And Development Co. Ltd. | Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines |
| CA2500715A1 (en) | 2002-10-03 | 2004-04-15 | Epimmune Inc. | Hla binding peptides and their uses |
| AU2003271904B2 (en) | 2002-10-09 | 2009-03-05 | Adaptimmune Limited | Single chain recombinant T cell receptors |
| DE60327795D1 (de) | 2002-11-09 | 2009-07-09 | Immunocore Ltd | T zell rezeptor "display" |
| GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| GB0318096D0 (en) * | 2003-08-01 | 2003-09-03 | Queen Mary & Westfield College | Vaccine |
| US20050053988A1 (en) | 2003-08-08 | 2005-03-10 | The Gov. Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services | Gene expressed in breast cancer and methods of use |
| WO2012079878A2 (en) * | 2010-12-14 | 2012-06-21 | Immatics Biotechnologies Gmbh | Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof |
| US20090298108A1 (en) | 2005-02-28 | 2009-12-03 | Joachim Schultz | Method for Identifying PDE11 Modulators |
| DE602006014106D1 (de) * | 2005-03-14 | 2010-06-17 | Link Genomics Inc | Verfahren zur diagnose von prostatakrebs |
| ES2341802T3 (es) | 2005-09-05 | 2010-06-28 | Immatics Biotechnologies Gmbh | Peptidos asociados a tumores unidos promiscuamente a moleculas del antigeno de leucocito humano (hla) de clase ii. |
| AU2006308863A1 (en) | 2005-10-31 | 2007-05-10 | Janssen Pharmaceutica N.V. | A polypeptide complex of TRPM8 and calmodulin and its uses thereof |
| US20130332133A1 (en) * | 2006-05-11 | 2013-12-12 | Ramot At Tel Aviv University Ltd. | Classification of Protein Sequences and Uses of Classified Proteins |
| US20090263574A1 (en) | 2008-04-21 | 2009-10-22 | Quinn Daniel E | Method of restoring an article |
| EP2300040A4 (en) | 2008-05-01 | 2012-06-27 | Beth Israel Hospital | METHOD AND COMPOSITIONS FOR IMMUNOTHERAPY IN PROSTATE CANCER |
| SI2119726T2 (en) * | 2008-05-14 | 2018-03-30 | Immatics Biotechnologies Gmbh | New and powerful Class II MHC peptides derived from survivin and neurocane |
| WO2010037395A2 (en) * | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| PL2172211T3 (pl) | 2008-10-01 | 2015-05-29 | Immatics Biotechnologies Gmbh | Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka |
| WO2010102157A1 (en) | 2009-03-04 | 2010-09-10 | The Regents Of The University Of California | Molecular predictors of biological response to a cenpe inhibitor in cancer |
| WO2013040142A2 (en) * | 2011-09-16 | 2013-03-21 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
| EP4012714A1 (en) * | 2010-03-23 | 2022-06-15 | Iogenetics, LLC. | Bioinformatic processes for determination of peptide binding |
| GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| SG10201505564VA (en) * | 2010-07-15 | 2015-09-29 | Oleg Iliich Epshtein | Combination pharmaceutical composition and methods of treating genitourinary system disorders |
| US20120121592A1 (en) * | 2010-10-13 | 2012-05-17 | Baylor Research Institute | Targeting Antigens to Human Dendritic Cells Via DC-Asialoglycoprotein Receptor to Produce IL-10 Regulatory T-Cells |
| US20140170168A1 (en) | 2010-10-26 | 2014-06-19 | Yoram Reiter | Antibodies which bind soluble t-cell receptor ligands |
| WO2013057586A1 (en) | 2011-10-19 | 2013-04-25 | Oslo Universitetssykehus Hf | Compositions and methods for producing soluble t - cell receptors |
| AU2013243948A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
| CN105163754B (zh) | 2012-09-20 | 2018-01-05 | 王荣福 | 前列腺特异性肿瘤抗原及其用途 |
| US12540318B2 (en) | 2012-11-08 | 2026-02-03 | Roche Diagnostics Operations, Inc. | Nucleic acids encoding chimeric polypeptides for library screening |
| EP2808392A1 (en) | 2013-05-28 | 2014-12-03 | Rheinische Friedrich-Wilhelms-Universität Bonn | Aptamers and use of the aptamers in the diagnosis and treatment of cancer |
| TWI775117B (zh) * | 2013-08-05 | 2022-08-21 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（二） |
| GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| GB201423361D0 (en) | 2014-12-30 | 2015-02-11 | Immatics Biotechnologies Gmbh | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
| WO2016138362A1 (en) * | 2015-02-26 | 2016-09-01 | The Board Of Trustees Of The University Of Arkansas | Treatment vaccine for prostate cancer |
| CA2988388C (en) * | 2015-04-23 | 2022-11-22 | Nantomics, Llc | Cancer neoepitopes |
| GB201513921D0 (en) | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| GB201520566D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| RU2020103379A (ru) * | 2017-07-04 | 2021-08-04 | Куревак Аг | Новые молекулы нуклеиновых кислот |
| MX2023007003A (es) | 2020-12-14 | 2023-08-18 | Biontech Us Inc | Antigenos especificos de tejidos para la inmunoterapia del cancer. |
-
2015
- 2015-08-06 GB GBGB1513921.5A patent/GB201513921D0/en not_active Ceased
-
2016
- 2016-08-04 AR ARP160102395A patent/AR105817A1/es not_active Application Discontinuation
- 2016-08-05 AU AU2016303021A patent/AU2016303021B2/en not_active Ceased
- 2016-08-05 MA MA46022A patent/MA46022B1/fr unknown
- 2016-08-05 SG SG10202001660YA patent/SG10202001660YA/en unknown
- 2016-08-05 MA MA053452A patent/MA53452A/fr unknown
- 2016-08-05 MX MX2018001421A patent/MX2018001421A/es unknown
- 2016-08-05 MD MDE20180586T patent/MD3331900T2/ro unknown
- 2016-08-05 CR CR20200434A patent/CR20200434A/es unknown
- 2016-08-05 ES ES16750766T patent/ES2862400T3/es active Active
- 2016-08-05 KR KR1020187005514A patent/KR102943979B1/ko active Active
- 2016-08-05 CR CR20200431A patent/CR20200431A/es unknown
- 2016-08-05 TW TW105124943A patent/TWI829618B/zh not_active IP Right Cessation
- 2016-08-05 UA UAA201800448A patent/UA125816C2/uk unknown
- 2016-08-05 CN CN202111376484.6A patent/CN114395013A/zh active Pending
- 2016-08-05 JP JP2018505723A patent/JP6884752B2/ja not_active Expired - Fee Related
- 2016-08-05 HR HRP20210709TT patent/HRP20210709T8/hr unknown
- 2016-08-05 LT LTEP16750766.4T patent/LT3331900T/lt unknown
- 2016-08-05 MA MA053680A patent/MA53680A/fr unknown
- 2016-08-05 EA EA201890440A patent/EA201890440A1/ru unknown
- 2016-08-05 CA CA3110640A patent/CA3110640A1/en active Pending
- 2016-08-05 CN CN201680045204.4A patent/CN107849107A/zh active Pending
- 2016-08-05 EP EP20216899.3A patent/EP3854801A3/en not_active Withdrawn
- 2016-08-05 WO PCT/EP2016/068727 patent/WO2017021527A2/en not_active Ceased
- 2016-08-05 PL PL16750766T patent/PL3331900T3/pl unknown
- 2016-08-05 TW TW109124889A patent/TW202106702A/zh unknown
- 2016-08-05 CR CR20200435A patent/CR20200435A/es unknown
- 2016-08-05 DK DK16750766.4T patent/DK3331900T3/da active
- 2016-08-05 PE PE2018000178A patent/PE20180695A1/es unknown
- 2016-08-05 PE PE2023002284A patent/PE20250557A1/es unknown
- 2016-08-05 HU HUE16750766A patent/HUE053657T2/hu unknown
- 2016-08-05 CR CR20200432A patent/CR20200432A/es unknown
- 2016-08-05 IL IL310078A patent/IL310078A/en unknown
- 2016-08-05 EP EP23216403.8A patent/EP4324472A3/en active Pending
- 2016-08-05 BR BR112018001687-0A patent/BR112018001687A2/pt not_active Application Discontinuation
- 2016-08-05 TW TW112150529A patent/TW202415673A/zh unknown
- 2016-08-05 CA CA3110633A patent/CA3110633A1/en active Pending
- 2016-08-05 PT PT167507664T patent/PT3331900T/pt unknown
- 2016-08-05 CR CR20180074A patent/CR20180074A/es unknown
- 2016-08-05 EP EP16750766.4A patent/EP3331900B1/en active Active
- 2016-08-05 MY MYPI2018700247A patent/MY202812A/en unknown
- 2016-08-05 US US15/229,970 patent/US9908920B2/en not_active Expired - Fee Related
- 2016-08-05 MA MA41879A patent/MA41879A1/fr unknown
- 2016-08-05 SI SI201631144T patent/SI3331900T1/sl unknown
- 2016-08-05 RS RS20210446A patent/RS61713B1/sr unknown
- 2016-08-05 EP EP20216870.4A patent/EP3842446A1/en not_active Withdrawn
- 2016-08-05 MY MYPI2020006864A patent/MY200281A/en unknown
- 2016-08-05 CA CA2994771A patent/CA2994771C/en active Active
- 2016-08-05 MY MYPI2020006865A patent/MY203318A/en unknown
- 2016-08-05 CR CR20200433A patent/CR20200433A/es unknown
-
2017
- 2017-06-29 US US15/638,072 patent/US10155032B2/en active Active
- 2017-06-29 US US15/637,906 patent/US9993539B2/en active Active
- 2017-12-21 US US15/849,878 patent/US10500259B2/en active Active
-
2018
- 2018-01-24 ZA ZA2018/00513A patent/ZA201800513B/en unknown
- 2018-01-25 PH PH12018500189A patent/PH12018500189A1/en unknown
- 2018-02-01 MX MX2021015933A patent/MX2021015933A/es unknown
- 2018-02-04 IL IL257331A patent/IL257331A/en unknown
- 2018-02-05 CL CL2018000324A patent/CL2018000324A1/es unknown
- 2018-02-27 CO CONC2018/0002202A patent/CO2018002202A2/es unknown
- 2018-08-10 US US16/100,498 patent/US10383930B2/en active Active
- 2018-10-05 US US16/153,294 patent/US10238727B2/en active Active
- 2018-12-05 US US16/210,330 patent/US10376568B2/en active Active
-
2019
- 2019-04-16 US US16/385,221 patent/US10449238B2/en active Active
- 2019-04-16 US US16/385,225 patent/US10478480B2/en active Active
- 2019-07-10 US US16/507,375 patent/US10532091B1/en active Active
- 2019-08-27 US US16/552,873 patent/US10799569B2/en active Active
-
2020
- 2020-06-29 US US16/915,465 patent/US11058754B2/en active Active
- 2020-09-10 US US17/017,281 patent/US11065315B2/en not_active Expired - Fee Related
- 2020-11-18 JP JP2020191407A patent/JP7142957B2/ja active Active
-
2021
- 2021-02-26 CY CY20211100164T patent/CY1123854T1/el unknown
- 2021-04-01 AU AU2021202056A patent/AU2021202056B2/en not_active Ceased
- 2021-04-01 AU AU2021202059A patent/AU2021202059B2/en not_active Ceased
- 2021-04-01 AU AU2021202057A patent/AU2021202057B2/en not_active Ceased
- 2021-04-01 AU AU2021202058A patent/AU2021202058B2/en not_active Ceased
- 2021-04-01 AU AU2021202060A patent/AU2021202060B2/en not_active Ceased
- 2021-05-14 US US17/320,929 patent/US11786584B2/en active Active
- 2021-05-14 US US17/320,938 patent/US11826409B2/en active Active
- 2021-05-14 US US17/320,878 patent/US20210275653A1/en not_active Abandoned
- 2021-06-11 CL CL2021001544A patent/CL2021001544A1/es unknown
- 2021-06-11 CL CL2021001543A patent/CL2021001543A1/es unknown
- 2021-06-11 CL CL2021001542A patent/CL2021001542A1/es unknown
- 2021-06-11 CL CL2021001545A patent/CL2021001545A1/es unknown
- 2021-06-30 CL CL2021001744A patent/CL2021001744A1/es unknown
-
2022
- 2022-01-14 US US17/576,185 patent/US12076381B2/en active Active
- 2022-01-14 US US17/576,067 patent/US12102670B2/en active Active
- 2022-01-21 US US17/581,049 patent/US12097249B2/en active Active
- 2022-01-21 US US17/581,054 patent/US20220143163A1/en not_active Abandoned
- 2022-01-28 US US17/587,536 patent/US12144852B2/en active Active
- 2022-01-28 US US17/587,474 patent/US12180259B2/en active Active
- 2022-02-04 US US17/592,573 patent/US20220152175A1/en not_active Abandoned
- 2022-09-07 JP JP2022142129A patent/JP2022191218A/ja active Pending
- 2022-11-21 CL CL2022003264A patent/CL2022003264A1/es unknown
-
2023
- 2023-07-13 AU AU2023204661A patent/AU2023204661A1/en not_active Abandoned
- 2023-08-17 US US18/451,216 patent/US20240016908A1/en active Pending
- 2023-09-22 AU AU2023233214A patent/AU2023233214A1/en not_active Abandoned
-
2024
- 2024-12-10 JP JP2024215091A patent/JP2025038025A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018529320A5 (2) | ||
| JP2019510465A5 (2) | ||
| JP2018510628A5 (2) | ||
| JP2019502360A5 (2) | ||
| JP2021168652A5 (2) | ||
| JP2018519243A5 (2) | ||
| JP2018511321A5 (2) | ||
| JP2018518937A5 (2) | ||
| JP2019506838A5 (2) | ||
| JP2018509135A5 (2) | ||
| JP2018536383A5 (2) | ||
| JP2018520653A5 (2) | ||
| JP2019511214A5 (2) | ||
| JP2024099580A5 (2) | ||
| JP2018521641A5 (2) | ||
| JP2024041841A5 (2) | ||
| JP2021514178A5 (2) | ||
| JP2017525336A5 (2) | ||
| JP2017502076A5 (2) | ||
| RU2017137142A (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака | |
| JP2018518956A5 (2) | ||
| JP2020530759A5 (2) | ||
| JP2021535900A5 (2) | ||
| JP2017524337A5 (2) | ||
| JP2021101700A5 (2) |